Conversion to sirolimus: a successful treatment for posttransplantation Kaposi's sarcoma.
about
Adapting the Stress Response: Viral Subversion of the mTOR Signaling PathwaySkin cancer in solid organ transplant recipients: are mTOR inhibitors a game changer?Incidence, risk factors and outcome of de novo tumors in liver transplant recipients focusing on alcoholic cirrhosisMolecularly targeted therapy for Kaposi's sarcoma in a kidney transplant patient: case report, "what worked and what did not".Topical rapamycin inhibits tuberous sclerosis tumor growth in a nude mouse model.Conversion to sirolimus immunosuppression in liver transplantation recipients with hepatocellular carcinoma: Report of an initial experienceThe PIK3CA gene as a mutated target for cancer therapy.Molecular mechanisms deployed by virally encoded G protein-coupled receptors in human diseases.Amplification of the angiogenic signal through the activation of the TSC/mTOR/HIF axis by the KSHV vGPCR in Kaposi's sarcomaA phase I/II study of the safety and efficacy of the addition of sirolimus to tacrolimus/methotrexate graft versus host disease prophylaxis after allogeneic haematopoietic cell transplantation in paediatric acute lymphoblastic leukaemia (ALL).Simultaneous inhibition of mTOR-containing complex 1 (mTORC1) and MNK induces apoptosis of cutaneous T-cell lymphoma (CTCL) cells.Rapalogs in viral cancers.Evolution and management of de novo neoplasm post-liver transplantation: a 20-year experience from a single European centreTreatment of Kaposi sarcoma-associated herpesvirus-associated cancers.Kaposi's Sarcoma following Chronic Lymphocytic Leukemia: A Rare EntityMinimization vs tailoring: Where do we stand with personalized immunosuppression during renal transplantation in 2015?Management and prevention of post-transplant malignancies in kidney transplant recipientsSkin cancer as a contraindication to organ transplantation.Post-transplant de novo malignancies in renal transplant recipients: the past and present.Can mTOR inhibitors reduce the risk of late kidney allograft failure?Immunosuppression and tumor development in organ transplant recipients: the emerging dualistic role of rapamycin.Application of angiogenesis to clinical dermatology.Dual inhibition of PI3Kalpha and mTOR as an alternative treatment for Kaposi's sarcoma.Targeting the Mammalian Target of Rapamycin (mTOR) in Cancer Therapy: Lessons from Past and Future PerspectivesConsiderations in sirolimus use in the early and late post-transplant periods.The rationale for mTOR inhibition in epithelial ovarian cancer.SIRT1-mediated downregulation of p27Kip1 is essential for overcoming contact inhibition of Kaposi's sarcoma-associated herpesvirus transformed cellsEverolimus: efficacy and safety in cardiac transplantation.Viral oncogenesis and its role in nonmelanoma skin cancer.Post-transplant malignancy: reducing the risk in kidney transplant recipients.Proliferation signal inhibitors and post-transplant malignancies in heart transplantation: practical clinical management questions.Clinical application of mTORi based immunosuppression for renal transplantation in India.Phosphorylation events during viral infections provide potential therapeutic targets.An evaluation of sirolimus in renal transplantation.A drug safety evaluation of everolimus in kidney transplantation.Effect of maintenance immunosuppressive drugs on virus pathobiology: evidence and potential mechanisms.mTOR inhibitors and renal allograft: Yin and Yang.Skin cancer in kidney transplant recipients.Non-melanoma skin cancer is reduced after switch of immunosuppression to mTOR-inhibitors in organ transplant recipients.Mammalian target of rapamycin inhibition after solid organ transplantation: can it, and does it, reduce cancer risk?
P2860
Q26700049-7E3AD7E2-E65D-4865-851C-314B08091A8EQ26851436-280985BA-2A39-4F9C-8830-A0BB34D18397Q27025406-AC036C8F-42F7-48F7-8C08-8D17006ADBC5Q33280039-51546811-4BBC-4EEA-8228-6710FD73477AQ33316872-FF22BCEA-323D-4753-A18E-B28F1F13582FQ33371289-61388B83-519D-4F3B-AE69-CF37E2E26783Q33699378-3F9FFBEC-AE48-40F2-89C2-A8C88161025FQ33819076-BB14EBA5-86AE-499C-9229-0CAEED277EB8Q33895137-FC3ADE66-3242-4C08-AFD6-4DF1F1E5F9FAQ33924570-65748F65-7CFE-4D67-89C0-D048E5BA83FFQ34031521-1643AB9E-5E98-4FC9-B809-45E8F1AC4CACQ34160579-317DD970-C2B5-4DBB-AE84-C7CCF796DD96Q34959580-333007F4-9C2A-4887-9F83-5056D719D1DFQ35895560-05EE5730-9FE9-47EE-A836-711787924EADQ36035984-6AA9FFEA-72D0-407E-B75D-D260FCF19410Q36087779-517CE701-B491-487B-8F73-503DCAA858ABQ36088854-2A0E7B0E-1F37-41D3-A4AE-0405ECB392C7Q36226526-CAE10BD2-7FDE-4AE0-893F-79E187CAE3E1Q36530274-F7F66F7A-F3AB-4B47-B442-6E351CEE8992Q36884566-FDE3D714-324E-42B7-8B35-A89AC7B1BDD2Q37028215-AF563A15-0EB5-4EEA-AD9A-783687A63EFEQ37079239-CF92856F-55A6-41EC-B1AD-5169F5182EF8Q37104658-636E485B-6BF5-4D1F-B114-E60E3DA48842Q37132788-A33DADE2-5E42-40A4-AC27-32ED1E9D100DQ37517602-E909DFE1-BBE3-46A7-9731-6259945326B7Q37627253-45589DA2-DF3E-497C-998D-9309D0EB5027Q37689009-4060F867-2E01-4689-9CCD-78E6D25FBA59Q37779322-8F44D92A-4417-4AF5-B865-72ADFDDB5DC1Q37854816-E4B283CC-295D-4D3E-8978-183F7FEF5848Q37863680-C0DCFE70-DED5-46BB-8B62-EE7874066333Q37876951-45274E3D-FBC5-4847-ACF6-6E44F1F08CA1Q37929851-3FD275DA-18F4-42DA-9A78-C9B2A5046B45Q37960427-D6CA275E-E4F6-437B-9D84-808C635C4EF0Q38038696-3358B194-2D4E-40F3-BF21-F3B34144237FQ38041260-7C6E090C-C113-4186-9B44-FBDC5FEAC635Q38061056-609AC213-1DE1-44C4-8DA0-1FD7209BDCFDQ38209973-74B706AC-E6A3-4A83-B278-3707DE30C744Q38210273-CE0B1D79-15F4-4A27-BF82-349DD7A4CCFCQ38210623-4CDA960A-6AB4-4E17-8833-AFFEB06DA4AFQ38533271-1EE6DB24-69B1-4BCD-9A9A-4B8C21E486CC
P2860
Conversion to sirolimus: a successful treatment for posttransplantation Kaposi's sarcoma.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Conversion to sirolimus: a successful treatment for posttransplantation Kaposi's sarcoma.
@en
Conversion to sirolimus: a successful treatment for posttransplantation Kaposi's sarcoma.
@nl
type
label
Conversion to sirolimus: a successful treatment for posttransplantation Kaposi's sarcoma.
@en
Conversion to sirolimus: a successful treatment for posttransplantation Kaposi's sarcoma.
@nl
prefLabel
Conversion to sirolimus: a successful treatment for posttransplantation Kaposi's sarcoma.
@en
Conversion to sirolimus: a successful treatment for posttransplantation Kaposi's sarcoma.
@nl
P2093
P1433
P1476
Conversion to sirolimus: a successful treatment for posttransplantation Kaposi's sarcoma.
@en
P2093
Alex Gutierrez-Dalmau
J Vicente Torregrosa
Josep M Campistol
P304
P356
10.1097/01.TP.0000115344.18025.0B
P577
2004-03-01T00:00:00Z